eligibility_summary
Eligibility: Ages 0–26 with B‑cell precursor ALL or B‑cell lymphoma. Arm A: relapsed/refractory after standard chemo without immunotherapy, or previously treated with SOC FDA‑approved immunotherapy (e.g., tisagenlecleucel/Kymriah, blinatumomab). Arm B: same disease/age, planned for SOC CAR‑T (tisagenlecleucel, incl. leukapheresis), blinatumomab, or inotuzumab, or relapsed/refractory. Informed consent required, LAR for minors, assent >7 as appropriate.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational study of pediatric/young adult B‑cell ALL/lymphoma outcomes after commercial immunotherapy: tisagenlecleucel (Kymriah), blinatumomab, and inotuzumab ozogamicin. Mechanisms/types: • Tisagenlecleucel—autologous anti‑CD19 CAR T‑cell therapy (gene‑modified adoptive cell therapy, 4‑1BB costimulation) redirecting patient T cells to lyse CD19+ B cells. • Blinatumomab—bispecific T‑cell engager (BiTE) antibody linking CD19 on B cells to CD3 on T cells, activating cytotoxic T‑cell killing. • Inotuzumab ozogamicin—anti‑CD22 antibody‑drug conjugate delivering calicheamicin, causing DNA double‑strand breaks after internalization. Targets/pathways: CD19 and CD22 on malignant B cells, CD3/T‑cell activation, resultant B‑cell depletion and tumor lysis. Study collects retrospective/prospective outcomes, biosamples, and patient‑reported outcomes.